Submit your cannabis health questions and receive informational responses from credentialed healthcare professionals in our network.
0/1000 characters
Questions are reviewed before publication. We do not publish personally identifying information.
Responses from credentialed healthcare professionals in our network. All responses are informational only.
Q: What is a safe starting dose of CBD for someone who has never used cannabis before and wants to try it for anxiety?
For a cannabis-naive adult using CBD for anxiety, the general clinical recommendation is to start with 5–10mg of CBD once daily, preferably in the evening. This "start low, go slow" approach allows you to assess your individual response before increasing. After 1–2 weeks at the starting dose with no adverse effects, you may cautiously increase by 5mg increments. Most clinical studies on CBD for anxiety have used doses ranging from 25–75mg/day, but individual response varies significantly based on body weight, metabolism, and the specific anxiety disorder. Full-spectrum CBD products may offer enhanced effects at lower doses due to the entourage effect. Sublingual administration (under the tongue) provides faster onset (15–45 minutes) compared to oral capsules (1–2 hours).
This response is informational only and does not constitute medical advice, diagnosis, or treatment. It does not establish a physician-patient relationship. Always consult your licensed healthcare provider before making medical decisions.
Q: I take warfarin for atrial fibrillation. Is it safe to use CBD oil? My cardiologist hasn't given me a clear answer.
This is an important safety question. CBD is a known inhibitor of CYP2C9, the primary enzyme responsible for warfarin metabolism. This means CBD can increase warfarin blood levels, potentially raising your INR and bleeding risk. Multiple case reports have documented clinically significant warfarin-CBD interactions. If you and your physician decide to trial CBD, it is essential that your INR be monitored more frequently — at least weekly initially — and your warfarin dose adjusted accordingly. I would strongly encourage you to bring published literature on this interaction to your next cardiology appointment. The interaction is well-documented and your INR management plan should be updated before starting any CBD product. Do not start CBD with warfarin without explicit physician supervision and a monitoring plan.
This response is informational only and does not constitute medical advice, diagnosis, or treatment. It does not establish a physician-patient relationship. Always consult your licensed healthcare provider before making medical decisions.
Q: My 8-year-old has Dravet syndrome and we're considering CBD. What should we know before talking to her neurologist?
CBD (cannabidiol) has the strongest evidence base in pediatric epilepsy, specifically for Dravet syndrome and Lennox-Gastaut syndrome. Epidiolex (pharmaceutical-grade CBD) received FDA approval in 2018 specifically for these conditions and is the only cannabis-derived medication with full FDA approval. Key points for your neurologist conversation: (1) Epidiolex is the appropriate formulation — not over-the-counter CBD products, which lack pharmaceutical-grade quality control; (2) Clinical trials showed a median 39% reduction in convulsive seizures vs. 13% for placebo; (3) Common side effects include somnolence, decreased appetite, and elevated liver enzymes requiring monitoring; (4) Interactions with clobazam (a common Dravet medication) can increase clobazam levels. Your neurologist should be familiar with the GWPCARE trials. If they are not, consider requesting a referral to a pediatric epilepsy center with cannabis experience.
This response is informational only and does not constitute medical advice, diagnosis, or treatment. It does not establish a physician-patient relationship. Always consult your licensed healthcare provider before making medical decisions.
Q: What is the difference between full-spectrum, broad-spectrum, and CBD isolate? Which is best for pain?
These three categories differ in their cannabinoid and terpene content: Full-spectrum contains all naturally occurring cannabinoids including THC (up to 0.3% in hemp-derived products), CBD, CBG, CBN, terpenes, and flavonoids. The "entourage effect" theory suggests these compounds work synergistically. Broad-spectrum contains all cannabinoids and terpenes except THC — suitable for those who cannot have any THC (drug testing, sensitivity). CBD isolate is pure CBD with no other compounds — predictable dosing but may require higher doses for equivalent effect. For pain specifically, the limited clinical evidence slightly favors full-spectrum products due to the entourage effect, and THC has more robust evidence for pain than CBD alone. However, if you are subject to drug testing or sensitive to THC, broad-spectrum is a reasonable alternative. Isolate is best when precise, consistent dosing is the priority. Always look for products with third-party Certificates of Analysis (COA) verifying cannabinoid content and absence of contaminants.
This response is informational only and does not constitute medical advice, diagnosis, or treatment. It does not establish a physician-patient relationship. Always consult your licensed healthcare provider before making medical decisions.
Q: I've been using cannabis for sleep for 3 months and now I can't sleep without it. Is this dependence? What should I do?
What you're describing is consistent with cannabis use disorder (CUD) or cannabis dependence, which affects approximately 9% of people who use cannabis and up to 17% of those who start in adulthood. Sleep disruption is one of the most common cannabis withdrawal symptoms and can persist for 1–3 weeks after cessation. This is because THC suppresses REM sleep, and upon stopping, there is a REM rebound effect causing vivid dreams and disrupted sleep. This does not mean you cannot stop — it means stopping should be done thoughtfully. Recommended approach: (1) Speak honestly with your physician about your cannabis use and sleep concerns; (2) Consider a gradual taper rather than abrupt cessation; (3) Cognitive Behavioral Therapy for Insomnia (CBT-I) has strong evidence as a non-pharmacological sleep intervention; (4) Short-term sleep hygiene interventions can help bridge the withdrawal period. You are not alone — this is a recognized and treatable condition.
This response is informational only and does not constitute medical advice, diagnosis, or treatment. It does not establish a physician-patient relationship. Always consult your licensed healthcare provider before making medical decisions.
Q: I have a medical cannabis card in California but I travel frequently for work. What are the federal and interstate travel rules?
This is a critical legal question and the answer is unambiguous: cannabis remains a Schedule I controlled substance under federal law regardless of state medical programs. This has several important implications: (1) Air travel: TSA operates under federal jurisdiction. Carrying cannabis on any flight — including between two legal states — is federally illegal. TSA's stated policy is to refer cannabis findings to law enforcement. (2) Interstate travel by car: Crossing state lines with cannabis is federal drug trafficking, even between two legal states. (3) Federal property: National parks, federal buildings, and military bases are federal jurisdiction — cannabis is prohibited. (4) State-to-state variation: Some states do not recognize out-of-state medical cards. Always research the specific laws of your destination state. The safest approach for frequent travelers is to purchase cannabis legally in each destination state rather than transporting it. This information is general and not legal advice — consult a cannabis attorney for your specific situation.
This response is informational only and does not constitute medical advice, diagnosis, or treatment. It does not establish a physician-patient relationship. Always consult your licensed healthcare provider before making medical decisions.
Q: How long does it take for CBD to work for chronic pain, and how do I know if it's actually helping?
CBD's timeline for chronic pain varies by administration route and individual factors. Sublingual (under tongue): onset 15–45 minutes, peak 1–2 hours, duration 4–6 hours. Oral capsules/edibles: onset 1–2 hours, peak 2–4 hours, duration 6–8 hours. Topical: onset 15–45 minutes, localized effect only. For chronic conditions, most clinical evidence suggests a therapeutic trial of at least 4–8 weeks at consistent dosing before evaluating efficacy. To objectively assess whether CBD is helping, I recommend: (1) Use the Symptom Tracker tool on this site to log daily pain scores (0–10) before starting; (2) Track sleep quality, mood, and functional ability alongside pain; (3) Note any medication changes during the trial period; (4) Bring your tracking data to your physician. A meaningful response is generally considered a ≥30% reduction in pain scores. If you see no improvement after 8 weeks at an adequate dose, CBD may not be the right intervention for your specific pain type.
This response is informational only and does not constitute medical advice, diagnosis, or treatment. It does not establish a physician-patient relationship. Always consult your licensed healthcare provider before making medical decisions.
Q: Can cannabis help with Crohn's disease? My gastroenterologist is skeptical but I've read positive things online.
The evidence for cannabis in Crohn's disease is genuinely promising but still evolving, which may explain your gastroenterologist's caution. Here's an honest summary of the current evidence: Positive findings: A 2013 Israeli RCT (Naftali et al.) found that THC-rich cannabis induced clinical remission in 45% of patients vs. 10% placebo. Multiple observational studies report significant symptom improvement in nausea, abdominal pain, and appetite. Limitations: Most studies are small, short-term, and use patient-reported outcomes rather than endoscopic remission. Cannabis does not appear to reduce intestinal inflammation at the mucosal level in most studies. Current position: The Crohn's & Colitis Foundation acknowledges cannabis may help with symptom management but does not recommend it as a primary treatment for inducing or maintaining remission. A reasonable approach: discuss cannabis as an adjunct for symptom control (pain, nausea, appetite) while continuing your prescribed IBD therapy. Bring the Naftali 2013 paper and the 2021 Cochrane review to your next GI appointment as a starting point for the conversation.
This response is informational only and does not constitute medical advice, diagnosis, or treatment. It does not establish a physician-patient relationship. Always consult your licensed healthcare provider before making medical decisions.